cGMP PDE 5 Inhibitors for inhalation in the treatment of sexual dysfunction
OwnerReto Naefinventor
Life of this patent
Estimating the term…
Abstract
Treatment of sexual dysfunction by inhalation of a cGMP PDE 5 inhibitor, especially 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl) quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl) quinazoline, 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one or 1-cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin-4-one.
Claims20
A method of treating sexual dysfunction which comprises administering by inhalation an effective amount of an inhibitor of cGMP PDE 5 to a subject in need of such treatment.
A method according to claim S, in which said inhalable form is a finely divided particulate form comprising said inhibitor in finely divided particulate form, optionally together with a particulate carrier.
A medicament comprising a cGMP PDE 5 inhibitor as disclosed in WO94/28902, WO96/16657, WO98/49166, EP-A-0636626 or U.S. Pat. No. 5,436,233 in inhalable form.
Dependencies are inferred from the claim text.